Hyalgan

Hyalgan is an injectable solution that contains 10 mg/2 mL of sodium hyaluronate, a hyaluronic‑acid derivative used as a viscosupplement. It is a prescription‑only product marketed in the European Union for intra‑articular administration. The formulation is designed to supplement the natural synovial fluid in joints, helping to restore elasticity and lubrication that can be lost in degenerative joint conditions and may improve patient comfort during movement.

Hyalgan is indicated for the symptomatic treatment of osteoarthritis when conservative measures have not provided adequate relief. It is administered directly into the affected knee joint to supplement synovial fluid and support joint function. - Patients with mild to moderate knee osteoarthritis. - Individuals who have persistent knee pain despite physical therapy or oral analgesics. - Adults for whom surgical options are being considered but not yet indicated. - Use as part of a comprehensive osteoarthritis management plan that includes exercise and weight control. - May be repeated after a defined treatment course if clinical benefit diminishes.

Adverse reactions to intra‑articular Hyalgan are generally localized and transient, but systemic or severe events can occur rarely.

Common: - Mild pain, tenderness, or swelling at the injection site lasting a few days. - Transient warmth, flushing, or a feeling of heat in the treated knee. - Temporary stiffness or reduced range of motion that improves with activity. - Mild bruising, discoloration, or small hematoma around the injection area.

Serious: - Acute joint infection (septic arthritis) presenting with fever, severe pain, and swelling. - Allergic or hypersensitivity reaction, such as rash, urticaria, or angio‑edema. - Persistent joint effusion or severe inflammatory response requiring aspiration or corticosteroid therapy. - Rare reports of osteonecrosis, cartilage degradation, or joint instability.

Before using Hyalgan, clinicians should evaluate patient history and joint condition to minimize risks and ensure appropriate use. - Avoid intra‑articular injection in joints with active infection, septic arthritis, or skin lesions over the injection site. - Do not use in patients with known hypersensitivity to hyaluronic acid or any component of the formulation. - Exercise caution in individuals with severe joint deformity, advanced osteoarthritis, or compromised immune systems. - Pregnancy and lactation status are not well established; consider risk‑benefit before administration. - Monitor for signs of infection or allergic reaction after each injection and advise patients to report symptoms promptly. - Repeated courses should be spaced according to clinical guidelines to avoid cumulative joint irritation.

Hyalgan is administered locally, yet certain systemic medications or procedures may influence its safety or efficacy.

Avoid: - Concurrent intra‑articular corticosteroid injections within two weeks, which can diminish the viscoelastic effect. - Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) that increase the risk of joint bleeding. - Live vaccines administered shortly after injection, due to potential immune modulation.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may mask early signs of joint infection. - Disease‑modifying antirheumatic drugs (DMARDs) or biologics that suppress immune response. - Physical therapy or vigorous joint loading immediately after injection, which could exacerbate local irritation.